Protagonist Therapeutics, Inc. (PTGX)
PTGX moved a median of -0.24% 30 minutes after news, and +0.20% by the close. How PTGX actually reacts to news — the realized, point-in-time move the market made, measured across 335 labeled events over the last three years with zero look-ahead.
PTGX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.27% | 44% | 332 |
| 30-min | -0.24% | 43% | 333 |
| 60-min | -0.08% | 48% | 333 |
| to close | +0.20% | 53% | 334 |
| Middle 50% of PTGX reactions | -1.47% to +0.90% |
|---|---|
| Median reaction (30-min) | -0.24% |
| Measured reactions | 335 |
Half of all Protagonist Therapeutics, Inc. news events land between -1.47% and +0.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PTGX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.72% | 33% | -0.97% |
| Coverage initiations | 27 | +0.23% | 52% | -0.69% |
| Rating reiterations | 118 | +0.03% | 51% | +0.40% |
| Price-target raises | 33 | -0.01% | 49% | +0.94% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how PTGX ranks against every other measured name →
That’s how PTGX usually reacts — get an email when it moves on news →Email me when PTGX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PTGX's baseline. Nothing else.
Recent PTGX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Protagonist Therapeutics Announces $300 Million Share Repurchase Program | Press release | ACCESS Newswire | +0.08% | -0.66% | |
| Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 | Press release | ACCESS Newswire | +0.00% | -1.30% | |
| Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera | Press release | ACCESS Newswire | -0.56% | +3.13% | |
| Protagonist Therapeutics Reports Granting of Inducement Awards | Press release | ACCESS Newswire | -2.37% | -3.65% | |
| Form 10-Q Protagonist Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.72% | +0.81% | |
| Form 8-K Protagonist Therapeutics For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | +0.81% | |
| Form S-8 Protagonist Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -0.72% | +0.81% | |
| Form S-8 POS Protagonist Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -0.72% | +0.81% | |
| Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -0.72% | +0.81% | |
| Protagonist Therapeutics Reports Granting of Inducement Awards | Press release | ACCESS Newswire | +0.29% | -0.12% | |
| Protagonist Therapeutics Reports Granting of Inducement Awards | Press release | ACCESS Newswire | +1.08% | +7.26% | |
| Protagonist Therapeutics Reports Granting of Inducement Awards | Press release | ACCESS Newswire | -0.02% | +4.55% | |
| Form 8-K Protagonist Therapeutics For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | +1.58% | |
| Protagonist Therapeutics Reports Granting of Inducement Awards | Press release | ACCESS Newswire | -0.34% | +0.54% | |
| Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress | Press release | ACCESS Newswire | +0.01% | -3.02% | |
| Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 | Press release | ACCESS Newswire | -0.11% | -2.27% | |
| Form 10-Q Protagonist Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.51% | +0.94% | |
| Form 8-K Protagonist Therapeutics For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -1.51% | +0.94% | |
| Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -1.51% | +0.94% | |
| Form ARS Protagonist Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.47% | -1.75% | |
| Form DEF 14A Protagonist Therapeutics For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | -0.47% | -1.75% | |
| Form DEFA14A Protagonist Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -0.47% | -1.75% | |
| Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | Press release | ACCESS Newswire | +1.23% | +1.72% | |
| Protagonist Therapeutics Reports Granting of Inducement Awards | Press release | ACCESS Newswire | -1.95% | +0.39% | |
| Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting | Press release | ACCESS Newswire | +0.21% | +0.84% | |
| Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis | Press release | ACCESS Newswire | -5.83% | +0.05% | |
| CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -0.94% | +1.02% | |
| Form 10-K Protagonist Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.94% | +1.02% | |
| Form 8-K Protagonist Therapeutics For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | +1.02% | |
| Form S-8 Protagonist Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -0.94% | +1.02% | |
| Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -0.94% | +1.02% | |
| Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 | Press release | ACCESS Newswire | +0.18% | +0.77% | |
| Form 8-K Protagonist Therapeutics For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +0.96% | |
| Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 | Press release | ACCESS Newswire | -2.14% | -0.42% | |
| Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | Press release | ACCESS Newswire | -0.24% | +0.00% | |
| Form 10-Q Protagonist Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.86% | -0.72% | |
| Form 8-K Protagonist Therapeutics For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -2.86% | -0.72% | |
| Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -2.86% | -0.72% | |
| Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting | Press release | ACCESS Newswire | +0.17% | +1.41% | |
| Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences | Press release | ACCESS Newswire | +0.74% | +0.16% | |
| Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill | Press release | ACCESS Newswire | -1.96% | +1.88% | |
| Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress | Press release | ACCESS Newswire | -0.11% | -1.38% | |
| Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 | Press release | ACCESS Newswire | +0.23% | -0.49% | |
| Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency | Press release | ACCESS Newswire | +0.60% | +3.23% | |
| Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 | Press release | ACCESS Newswire | +1.98% | +8.32% | |
| Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera | Press release | ACCESS Newswire | +1.41% | -1.04% | |
| Form 10-Q Protagonist Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.15% | -5.84% | |
| Form 8-K Protagonist Therapeutics For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -5.84% | |
| Form S-3ASR Protagonist Therapeutics | SEC filing · Form S-3ASR | SEC EDGAR | +0.15% | -5.84% | |
| Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | +0.15% | -5.84% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PTGX section they belong to.
Where else PTGX is measured.
PTGX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cardinal Health, Inc. (CAH) | 335 | +0.02% | 52% |
| MannKind Corporation (MNKD) | 335 | -0.25% | 43% |
| MYOS RENS TECH INC COMMON (MYOS) | 334 | 0.00% | 43% |
| Actelis Networks, Inc. (ASNS) | 331 | -0.83% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Protagonist Therapeutics, Inc.'s median reaction calculated?
Every labeled PTGX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 335 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of PTGX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PTGX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.